Abstract:Background: The Bacillus Calmette-Guérin (BCG) vaccine, currently the sole authorized vaccine against tuberculosis (TB), demonstrates limited effectiveness in safeguarding adolescents and adults from active TB, even when administered as a booster with either BCG itself or heterologous vaccine candidates. To effectively control the persistent epidemic of adult TB, it is imperative to investigate the mechanisms responsible for the suboptimal efficacy of the BCG prime-boosting strategy against primary Mycobacterium tuberculosis (M.tb) infection. Methods: C57BL/6J mice were immunized with the BCG vaccine either once or twice, followed by analysis of lung tissue to assess changes in cytokine levels. Additionally, varying intervals between vaccinations and detection times were examined to study IL-10 expression across different organs. IL-10-expressing cells in the lungs, spleen, and lymph nodes were analyzed through FACS and intracellular cytokine staining (ICS). BCG-revaccinated IL-10-/- mutant mice were compared with wild-type mice to evaluate antigen-specific IgG antibody and T cell responses. Protection against M.tb aerosol challenge was evaluated in BCG-revaccinated mice, either untreated or treated with anti-IL-10R monoclonal antibody. Results: IL-10 was significantly upregulated in the lungs of BCG-revaccinated mice shortly after the booster immunization. IL-10 expression peaked in the lungs 3-6 weeks post-revaccination and was also detected in lymph nodes and spleen as early as 2 weeks following the booster dose, regardless of the intervals between the prime and booster vaccinations. The primary sources of IL-10 in these tissues were identified as macrophages and dendritic cells. Blocking IL-10 signaling in BCG-revaccinated mice-either by using IL-10-/- mutant mice or administering anti-IL-10R monoclonal antibody increased levels of antigen-specific IFN-γ+ or IL-2+ CD4+ T cells, enhanced central and effector memory CD4+ T cell responses, and provided better protection against aerosol infection with 300 CFUs of M.tb. Conclusion: Our findings are crucial for formulating effective immunization strategies related to the BCG vaccine and for developing efficacious adult TB vaccines.

Protocol for analyzing BCG-induced trained immunity in murine bone marrow-derived macrophages

Airway Macrophages Mediate Mucosal Vaccine-Induced Trained Innate Immunity against Mycobacterium tuberculosis in Early Stages of Infection.

BCG-induced trained immunity: history, mechanisms and potential applications

BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design

Lessons from Bacillus Calmette-Guérin: Harnessing Trained Immunity for Vaccine Development

Early transcriptomic response of innate immune cells to subcutaneous BCG vaccination of mice

Macrophages exploit the mannose receptor and JAK-STAT1-MHC-II pathway to drive antigen presentation and the antimycobacterial immune response after BCG vaccination

Evaluation Of A New Recombinant Bcg Which Contains Mycobacterial Antigen Ag85b-Mpt64(190-198)-Mtb8.4 In C57/Bl6 Mice

Enhanced Protective Efficacy Against Mycobacterium Tuberculosis Afforded by BCG Prime‐dna Boost Regimen in an Early Challenge Mouse Model is Associated with Increased Splenic Interleukin‐2‐producing CD4 T‐cell Frequency Post‐vaccination

Mucosal recombinant BCG vaccine induces lung-resident memory macrophages and enhances trained immunity via mTORC2/HK1-mediated metabolic rewiring

Targeted Initiation of Trained Immunity in Tumor-Associated Macrophages with Membrane-Camouflaged Bacillus Calmette-Guérin for Lung Carcinoma Immunotherapy

Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut–lung axis

Plasma metabolome predicts trained immunity responses after antituberculosis BCG vaccination

PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4+ T cell transcriptomal molecular signatures

Multi-Level Proteomics Reveals Epigenetic Signatures in BCG-mediated Macrophage Activation

A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19

Mycobacterium bovis BCG vaccination induces memory CD4+ T cells characterized by effector biomarker expression and anti-mycobacterial activity

A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice

Nanocages engineered from Bacillus Calmette-Guerin facilitate protective Vγ2Vδ2 T cell immunity against Mycobacterium tuberculosis infection

Early introduction of IL-10 weakens BCG revaccination's protection by suppressing CD4+Th1 cell responses

Bacillus Calmette-Guérin (BCG) stimulates changes in dendritic cell surface marker expression in vitamin D-deficient mice